26 January 2012
EMA/47559/2012
Committee for Medicinal Products for Veterinary Use (CVMP)

CVMP Monthly report of application procedures, guidelines and related documents

January 2012

The CVMP monthly report includes statistical data for the current and previous two years on scientific advice, initial evaluations, variations, line extensions, renewals, MRLs initial evaluations and MRLs extensions/modifications and arbitration and referral procedures.

In addition, the report includes a summary table of the opinions issued by the CVMP in the current year and a list of adopted guidelines and other public documents.

Applications for medicinal products for veterinary use and maximum residue limits (MRLs)

Scientific advice requests

	95-09	2010	2011	2012	Total
Submitted	80	21	26	1	128
Advice given	73	18	24	2	117

Initial evaluation

	95-09	2010	2011	2012	Total
Full (Submitted)	124	16	8	1	149
Abridged/ generics (Submitted)	11	2	3	0	16
Withdrawals	12	1	0	0	13
Positive opinions	104	14	19	1	138
Negative opinions	1	0	0	0	1

Marketing authorisations

	95-09	2010	2011	2012	Total
Granted	100	9	22	1	132
Withdrawals	2	4	1	0	7
Not renewed	2	0	0	0	2

Extensions

	95-09	2010	2011	2012	Total
Submitted	72	3	7	0	82
Withdrawals	3	1	0	0	4
Positive opinions	47	8	4	0	59
Negative opinions	0	0	0	0	0

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8447
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Variations – applications submitted					
	95-09	2010	2011	2012	Total
Type IA	412	76	125	6	773
Type IB		63	87	4	
Type II	250	26	45	3	324
Transfers	14	8	3	1	26

Renewals					
	95-09	2010	2011	2012	Total
Submitted	68	7	14	0	89
Positive opinions	65	8	12	0	85
Negative opinions	0	0	0	0	0

Arbitrations and Community referrals					
	95-09	2010	2011	2012	Total
Referrals submitted	47	12	12	1	72
Opinions reached[1]	35 (5)	11 (1)	10	0	56 (6)

[1] Re-examination of opinions in brackets

Substances considered as not falling within the scope of Regulation (EC) No 470/2009			
	2011	2012	Total
Submitted	7	0	7
Agreed	9	0	9
Scientific advice recommended	0	0	0

MUMS/ Limited market classification			
	2011	2012	Total
Positive with financial incentives	8	3	11
Positive without financial incentives	12	0	12
Negative	1	0	1

Establishment of MRLs for new substances					
	95-09	2010	2011	2012	Total
Submitted	70	3	1	0	74
Withdrawals	5	0	0	0	5
Positive opinions[2]	56	2	4	0	62
Negative opinions[3]	7	0	0	0	7

Extensions / modifications/extrapolations of MRLs					
	95-09	2010	2011	2012	Total
Submitted	100	10	13	0	123
Withdrawals	4	0	2	0	6
Positive opinions[2]	116	3	12	0	131
Negative opinions	6	0	0	0	6

[2] Including opinions recommending the extension of the expiry date for provisional MRLS or definitive MRLs for substances with previously provisional maximum residue limits

[3] Including one opinion concluding that final MRL could not be established for a substance with provisional maximum residue limits previously established

CVMP opinions in 2012 on medicinal products for veterinary use

Positive opinions

Product • **Invented name** • **INN**	• **Marketing authorisation holder**	**Therapeutic area** • **Target species** • **Summary of indication**	**EMA/CVMP** • **Validation** • **Opinion** • **Active time** • **Clock stop**	**European Commission** • **Opinion received** • **Date of decision** • **Notification** • **Official Journal**
• Zulvac 1+8 Bovis • Inactivated Bluetongue virus, serotype 1 and 8, strain BTV-1	• Pfizer Limited	• Cattle • Vaccine for the active immunisation of cattle for the prevention of viraemia caused by Bluetongue Virus, serotype 1 and 8.	• 04/02/2011 • 12/01/2012 • 152 • 191	• 12/01/2012

Arbitrations and Community referrals in 2012

Type of referral	• **Date of clock start** • **CVMP opinion**	• **Product name** • **INN**
Referral under Art. 34 of Directive 2001/82/EC	• 09/11/2010	• Baytril 10% oral solution and associated names • Enrofloxacin
Referral under Art. 35 of Directive 2001/82/EC	• 09/03/2011	• Veterinary medicinal products containing active substances belonging to the class of flukicides for which no MRL has been established in milk
Referral under Art. 33(4) of Directive 2001/82/EC	• 04/05/2011	• Prontax 5 mg/ml pour-on solution for cattle • Doramectin
Referral under Art. 33(4) of Directive 2001/82/EC	• 04/05/2011	• Prontax 10 mg/ml solution for injection for sheep, cattle and pigs • Doramectin
Referral under Art. 35 of Directive 2001/82/EC	• 04/05/2011	• All pre-mixes for medicated feedingstuffs containing 40, 100 or 200 g tilmicosin per kg pre-mix • Tilmicosin
Referral under Art. 34 of Directive 2001/82/EC	• 14/09/2011	• Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus and Prazitel Plus and associated names • Praziquantel, pyrantel and febantel

Type of referral	• Date of clock start • CVMP opinion	• Product name • INN
Referral under Art. 35 of Directive 2001/82/EC	• 15/09/2011	• All long acting formulations for injection containing barium selenate for all food producing species • barium selenate
Procedure under Art. 30(3) of Regulation (EC) No 726/2004	• 15/09/2011	• N/a • Dapsone
Procedure under Article 33(4) of Directive 2001/82/EC	• 12/10/2011	• Nuflor 300 mg/ml solution for injection for cattle and sheep • Florfenicol
Procedure under Article 35 of Directive 2001/82/EC	• 12/10/2011	• Hipralona Enro-S and its generics • Enrofloxacin
Procedure under Article 33(4) of Directive 2001/82/EC	• 10/01/2012	• Nuflor Swine Once 450 mg/ml solution for injection • Florfenicol

Guidelines and working documents in 2011

CVMP Quality

Reference number	Document title	Status
EMA/CVMP/134/02-Rev.3	Draft guideline on the Active Substance Master File Procedure	Adopted for consultation, January 2012 (End of consultation 12 March 2012)
EMEA/CHMP/CVMP/QWP/17760/2009-Rev.1	Draft guideline on the Use of Near Infrared Spectroscopy by the Pharmaceutical Industry and the Data Requirements for New Submissions and Variations	Adopted for consultation, January 2012 (End of consultation 30 April 2012)

CVMP Efficacy

Reference number	Document title	Status
EMA/CVMP/EWP/81976/2010 replacing EMEA/CVMP/816/00	Guideline on Statistical principles for veterinary clinical trials.	Adopted January 2012

CVMP Safety

Reference number	Document title	Status
EMA/CVMP/SWP/355689/2006	Draft guideline on the approach to	Adopted for consultation,

Reference number	Document title	Status
	establish a pharmacological ADI.	January 2012) (End of consultation 31 July 2012)

CVMP Immunologicals

Reference number	Document title	Status
EMA/CVMP/IWP/810769/2011 replacing EMEA/CVMP/865/03/final	Guideline on data requirements for removing the target animal batch safety test for immunological veterinary medicinal products in the EU	Adopted January 2012